Volume 19 Issue 12
Dec.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(12): 1995-1998, 2027
QIAN Jing, HE Ze-lai, TIAN Xiao-yuan, JING Qi-jun, LI Hong-wei. Efficacy analysis of early radiotherapy versus delayed radiotherapy in 68 cases of EGFR-mutant lung adenocarcinoma with brain metastases[J]. Chinese Journal of General Practice, 2021, 19(12): 1995-1998, 2027. doi: 10.16766/j.cnki.issn.1674-4152.002219
Citation: QIAN Jing, HE Ze-lai, TIAN Xiao-yuan, JING Qi-jun, LI Hong-wei. Efficacy analysis of early radiotherapy versus delayed radiotherapy in 68 cases of EGFR-mutant lung adenocarcinoma with brain metastases[J]. Chinese Journal of General Practice, 2021, 19(12): 1995-1998, 2027. doi: 10.16766/j.cnki.issn.1674-4152.002219
shu

Efficacy analysis of early radiotherapy versus delayed radiotherapy in 68 cases of EGFR-mutant lung adenocarcinoma with brain metastases

doi: 10.16766/j.cnki.issn.1674-4152.002219
  • 1.

    Department of Radiation Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, China

Funds:

 81602727

 BYKY2019097ZD

  • Received Date: 2021-07-30
    Available Online: 2022-03-02
    Abstract
  •   Objective  To investigate the efficacy and influencing factors of early radiotherapy versus delayed radiotherapy in EGFR-mutant lung adenocarcinoma patients with brain metastasis.  Methods  A total of 68 cases of EGFR-mutant lung adenocarcinoma patients with brain metastases, who were admitted in the First Affiliated Hospital of Bengbu Medical College from January 1, 2016 to December 31, 2020. The patients were divided into two groups according to the timing of brain radiotherapy. The early radiotherapy group (n=48) received brain radiotherapy and epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) simultaneously. In the delayed radiotherapy group (n=20), EGFR-TKI was performed initially, and brain radiotherapy was performed after the brain lesions progressed. Intracranial progression-free survival (iPFS) and overall survival (OS) of the two groups were evaluated, and prognostic factors were analysed.  Results  The median OS of all patients was 26 months. The iPFS of the early radiotherapy group was prolonged compared with the delayed group. The 1-year, 2-year and 3-year iPFS rates were 91.3%, 73.5%, 61.3% and 74.3%, 60.8%, 30.4%, respectively (P=0.078). The OS of the early radiotherapy group was also longer than that of the delayed radiotherapy group. The OS rates were 81.6%, 51.5%, 51.5% and 65.0%, 51.2%, 20.5%, respectively, with no significant difference (P=0.321). The OS of patients with high Lung-mol GPA score was better than the OS of patients with low score (P < 0.001). Low ECOG score indicated good iPFS (P=0.010).  Conclusion  Compared with delayed radiotherapy, early radiotherapy may prolong iPFS and OS, but no significant statistical difference is found. ECOG and Lung-mol GPA are independent prognostic factors of iPFS and OS, respectively.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    SONG Y, WU Y L, CAO L J, et al. Efficacy and safety of gefitinib as third line treatment in NSCLC patients with activating EGFR mutations treated with first-line gefitinib followed by second-line chemotherapy: A single-arm, prospective, multicenter phase Ⅱ study (RECHALLENGE, CTONG1304)[J]. Am J Clin Oncol, 2019, 42(5): 432-439. doi: 10.1097/COC.0000000000000538
    [2]
    RAMALINGAM S S, VANSTEENKISTE J, PLANCHARD D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2020, 382(1): 41-50. doi: 10.1056/NEJMoa1913662
    [3]
    BROWN P D, JAECKLE K, BALLMAN K V, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial[J]. JAMA, 2016, 316(4): 401-409. doi: 10.1001/jama.2016.9839
    [4]
    ACHROL A S, RENNERT R C, ANDERS C, et al. Brain metastases[J]. Nat Rev Dis Primers, 2019, 5(1): 5. doi: 10.1038/s41572-018-0055-y
    [5]
    SPERDUTO P W, YANG T J, BEAL K, et al. Estimating survival in patients with lung cancer and brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA)[J]. JAMA Oncol, 2017, 3(6): 827-831. doi: 10.1001/jamaoncol.2016.3834
    [6]
    ZHU Q, SUN Y, CUI Y, et al. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)[J]. Oncotarget, 2017, 8(8): 13304-13311. doi: 10.18632/oncotarget.14515
    [7]
    CHEN Y, WEI J, CAI J, et al. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis[J]. BMC Cancer, 2019, 19(1): 793. doi: 10.1186/s12885-019-6005-6
    [8]
    MAGNUSON W J, LESTER-COLL N H, WU A J, et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor mutant non-small cell lung cancer: A retrospective multi-institutional analysis[J]. J Clin Oncol, 2017, 35(1): 1070-1077.
    [9]
    YU X, FAN Y. Real-World data on prognostic factors for overall survival in EGFR-Mutant Non-Small-Cell lung cancer patients with brain metastases[J]. J Cancer, 2019, 10(15): 3486-3493. doi: 10.7150/jca.30292
    [10]
    LI C, GUO J, ZHAO L, et al. Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma[J]. Cancer Manag Res, 2019, 11: 3433-3443. doi: 10.2147/CMAR.S196881
    [11]
    BYEON S, HAM J S, SUN J M, et al. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis[J]. Med Oncol, 2016, 33(8): 97. doi: 10.1007/s12032-016-0811-3
    [12]
    蒋一玲, 张传领, 陈承, 等. 贝伐珠单抗联合靶向治疗对EGFR突变型非小细胞肺癌患者的疗效观察[J]. 中华全科医学, 2021, 19(8): 1306-1309. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202108015.htm
    [13]
    JABLONSKA P A, BOSCH-BARRERA J, SERRANO D, et al. Challenges and novel opportunities of radiation therapy for brain metastases in non-small cell lung cancer[J]. Cancers (Basel), 2021, 13(9): 2141. doi: 10.3390/cancers13092141
    [14]
    SPERDUTO P W, YANG T J, BEAL K, et al. The effect of gene alterations and tyrosine kinase inhibition on survival and cause of death in patients with adenocarcinoma of the lung and brain metastases[J]. Int J Radiat Oncol Biol Phys, 2016, 96(2): 406-413. doi: 10.1016/j.ijrobp.2016.06.006
    [15]
    WU Y L, AHN M J, GARASSINO M C, et al. CNS efficacy of osimertinib in patients with T790M-Positive advanced non-small-cell lung cancer: Data From a randomized phase Ⅲ trial (AURA3)[J]. J Clin Oncol, 2018, 36(26): 2702-2709. doi: 10.1200/JCO.2018.77.9363
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (321) PDF downloads(7) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return